Clinical pharmacokinetics of tyrosine kinase inhibitors: Focus on 4-anilinoquinazolines

Clinical Pharmacokinetics

Volumn 50, Issue 6, 2011, Pages 371-403

  Scheffler, Matthias ^a   Di Gion, Paola ^a   Doroshyenko, Oxana ^a   Wolf, Jrgen ^a   Fuhr, Uwe ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antineoplastics; Cancer; Epidermal growth factor receptor antagonists; Erlotinib; Gefitinib; Genetic polymorphism; HER2 inhibitors; Lapatinib; Liver dysfunction; Quinazolines; Renal impairment

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; BILIRUBIN; CARBAMAZEPINE; EFAVIRENZ; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; INDINAVIR; IRINOTECAN; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; METOPROLOL; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SORAFENIB; TEMOZOLOMIDE; UNINDEXED DRUG;

ADVANCED CANCER; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHILDHOOD CANCER; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSFORMATION; FOOD DRUG INTERACTION; GENDER; GLIOBLASTOMA; GLIOMA; HUMAN; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PANCREAS CANCER; PHARMACOGENETICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RACE; RECOMMENDED DRUG DOSE; REVIEW; SMOKING; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; PHARMACOGENETICS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TISSUE DISTRIBUTION;

EID: 79955919708     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11587020-000000000-00000     Document Type: Review

References (155)

1. Van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35 (8): 692-706
2. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 2000; 59 (4): 753-67 (Pubitemid 30232318)
3. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor pro-duction and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7 (5): 1459-65 (Pubitemid 32708703)
4. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10 (4): 1212-8 (Pubitemid 38365209)
5. FukuokaM,YanoS,GiacconeG, etal. Multi-institutional randomizedphase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [published erratum appears in J Clin Oncol 2004; 22 (23): 4811]. J Clin Oncol 2003; 21 (12): 2237-46 (Pubitemid 46621858)
6. Kris MG, Natale RB, Herbst RS,et al. Efficacyofgefitinib, aninhibitorof the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290 (16): 2149-58 (Pubitemid 37432975)
7. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57 (21): 4838-48 (Pubitemid 27468992)
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353 (2): 123-32 (Pubitemid 41058344)
9. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25 (15): 1960-6 (Pubitemid 46972777)
10. Miksad RA, Schnipper L, Goldstein M. Does a statistically significant sur-vival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 2007; 25 (28): 4506-7 (Pubitemid 350013866)
11. Nelson MH, Dolder CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006; 40: 261-9 (Pubitemid 43269856)
12. Burris III HA, Taylor CW, Jones SF, et al. A phase I and pharmacokinetic study of oral lapatinib administration once or twice daily in patients with solid malignancies. Clin Cancer Res 2009; 15 (21): 6702-8
13. Bilancia D, Rosati G, Dinota A, et al. Lapatinib in breast cancer. Ann Oncol 2007; 18 (6): 26-30
14. Denny WA. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. Farmaco 2001; 56 (1-2): 51-6 (Pubitemid 32372583)
15. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265: 7709-12 (Pubitemid 20158927)
16. Pao W, Miller VA. Epidermal growth factor receptor mutations, small mol-ecule kinase inhibitors and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005; 23: 2556-68
17. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291 (2): 739-48. (Pubitemid 29503548)
18. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1 (2): 85-94.
19. Xia W, Mulin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-63.
20. Tevaarwerk AJ, KolesarJM. Lapatinib:asmall-molecule inhibitorofepidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009; 31 (2): 2332-48.
21. Govindan R. A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 2010; 11 (1): 8-12.
22. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101 (36): 13306-11. (Pubitemid 39209661)
23. Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR in- hibitors in non-small cell lung cancer. Curr Opin Oncol 2005; 17: 118-22. (Pubitemid 40516280)
24. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361 (10): 947-57.
25. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces anti- angiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62 (9): 2554-60. (Pubitemid 34462734)
26. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62 (20): 5749-54. (Pubitemid 35204731)
27. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28 Suppl. 1: 24-31.
28. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10 (4): 281-9.
29. Burris III HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal groth factor receptor tyrosine kinases, in heavily pre-treated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-13. (Pubitemid 46206984)
30. Choi YJ, Rho JK, Jeon BS, et al. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother Pharmacol 2010; 66 (2): 381-8.
31. Lawrence DS, Niu J. Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol Ther 1998; 77 (2): 81-114. (Pubitemid 28077909)
32. European Medicines Agency. Iressa® 250 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001016/WC500036358.pdf [Accessed 2011 Mar 16].
33. Tarceva® (erlotinib) tablets: US prescribing information [online]. Available from URL: http://www.gene.com/gene/products/information/pdf/tarceva- prescribing.pdf [Accessed 2011 Mar 16].
34. Polli JW, Humphreyes JE, Harmon KA, et al. The role of efflux and uptake transporters in N-3-chloro-4-[(3-fluorbenzyl)oxy]phenyl-6-[5([2-(methylsul- fonyl)ethyl]aminomethyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008; 36 (4): 695-701. (Pubitemid 351468376)
35. Tyverb® (lapatinib) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsat.fda-docs/label/2010/ 022059s007lbl.pdf [Accessed 2011 Mar 16].
36. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20 (18): 3815-25.
37. Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001; 40 (4): 297-306. (Pubitemid 32458155)
38. Jones HK, Stafford LE, Swaisland HC, et al. A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in phase I clinical trials. J Pharm Biomed Anal 2002; 29 (1-2): 221-8. (Pubitemid 34621284)
39. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19 (13): 3267-79. (Pubitemid 32591445)
40. Zhao M, He P, Rudek MA, et al. Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 793 (2): 413-20. (Pubitemid 37271981)
41. Lepper ER, Swain SM, Tan AR, et al. Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 796 (1): 181-8. (Pubitemid 38352722)
42. Masters AR, Sweeney CJ, Jones DR. The quantification of erlotinib (OSI774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848 (2): 379-83. (Pubitemid 46464049)
43. Zhang W, Siu LL, Moore MJ, et al. Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 814 (1): 143-7. (Pubitemid 40017946)
44. Bai F, Freeman III BB, Fraga CH, et al. Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr 2006; 831: 169-75. (Pubitemid 43155792)
45. Haouala A, Zanolari B, Rochat B, et al. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877 (22): 1982-96.
46. Roche S, McMahon G, Clynes M, et al. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877 (31): 3982-90.
47. Swaisland HC, Smith RP, Laight A, et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 2005; 44 (11): 1165-77. (Pubitemid 41483701)
48. Li J, Brahmer J, Messersmith W, et al. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 2006; 24 (4): 291-7.
49. Daw NC, Furman WL, Stewart CF, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol 2005; 23 (25): 6172-80.
50. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20 (9): 2240-50. (Pubitemid 34441651)
51. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003; 14 (6): 922-30. (Pubitemid 36827209)
52. Bergman E, Forsell P, Persson EM, et al. Pharmacokinetics of gefitinib in humans: the influenceofgastrointestinal factors. IntJPharm 2007; 341 (1-2): 134-42. (Pubitemid 47096678)
53. Cantarini MV, McFarquhar T, Smith RP, et al. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers. Clin Ther 2004; 26 (10): 1630-36. (Pubitemid 39643023)
54. Swaisland HC, Cantarini MV, Fuhr R, et al. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmaco-kinetics. Clin Pharmacokinet 2006; 45 (6): 633-44. (Pubitemid 44046489)
55. Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005; 44 (10): 1067-81. (Pubitemid 41356392)
56. Chhun S, Verstuyft C, Rizzo-Padoin N, et al. Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol 2009; 68 (2): 226-37.
57. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006; 12 (3 Pt 1): 860-8. (Pubitemid 43259869)
58. Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007; 13 (9): 2684-91. (Pubitemid 46788036)
59. Li J,Karlsson MO, BrahmerJ,etal. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 2006; 98 (23): 1714-23. (Pubitemid 44942709)
60. Ling J, Johnson KA, Miao Z, et al. Metabolism and excretion of erlotinib, a small molecule inhibitorofepidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 2006; 34 (3): 420-6. (Pubitemid 43290900)
61. Frohna P, Lu J, Eppler S, et al. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 2006; 46 (3): 282-90. (Pubitemid 43260315)
62. Lu JF, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006; 80 (2): 136-45. (Pubitemid 44160689)
63. Ling J, Fettner S, Lum BL, et al. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 2008; 19 (2): 209-16.
64. Ranson M, Shaw H, Wolf J, et al. A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer Chemother Pharmacol 2010; 66 (1): 53-8.
65. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008; 26 (7): 1119-27.
66. Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, anepidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004; 22 (15): 3080-90. (Pubitemid 41103720)
67. Yamamoto N, Horiike A, Fujisaka Y, et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2008; 61 (3): 489-96. (Pubitemid 350275984)
68. Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12 (7 Pt 1): 2166-71.
69. Hughes AN, O'Brien ME, Petty WJ, et al. Overcoming CYP1A1/1A2 mediated induction ofmetabolism byescalating erlotinib dose in current smokers. J Clin Oncol 2009; 27 (8): 1220-6.
70. Broniscer A, Baker SJ, Stewart CF, et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res 2009; 15 (2): 701-7.
71. Jakacki RI, Hamilton M, Gilbertson RG, et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide:aChildren's Oncology Group PhaseI Consortium study. J Clin Oncol 2008; 26 (30): 4921-7.
72. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007; 25 (21): 3055-60. (Pubitemid 47218052)
73. Messersmith WA, Laheru DA, Senzer NN, et al. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 2004; 10 (19): 6522-7. (Pubitemid 39346546)
74. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23 (11): 2544-55.
75. Van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group study 26034. J Clin Oncol 2009; 27(8): 1268-74.
76. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005; 11 (18): 6414-21. (Pubitemid 41338977)
77. Bence AK, Anderson EB, Halepota MA, et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 2005; 23: 39-49. (Pubitemid 39505950)
78. Nakagawa K, Minami H, Kanezaki M, et al. Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors. Jpn J Clin Oncol 2009; 39 (2): 116-23.
79. Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009; 27 (8): 1191-6.
80. Smith DA, Koch KM, Arya N, et al. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2009; 67 (4): 421-6.
81. Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmaco-kinetics and molecular correlation. Cancer Chemother Pharmacol 2010; 65 (2): 353-61.
82. Medina P, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clinical Ther 2008; 30 (8): 1426-47.
83. McKillop D, Hutchison M, Partridge EA, et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 2004; 34 (10): 917-34. (Pubitemid 39648170)
84. McKillop D, McCormick AD, Millar A, et al. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 2005; 35 (1): 39-50. (Pubitemid 40459216)
85. Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006; 24 (27): 4517-20. (Pubitemid 46630993)
86. Hofer S, Frei K, Rutz HP. Gefitinib accumulation in glioblastoma tissue. Cancer Biol Ther 2006; 5 (5): 483-4. (Pubitemid 43765281)
87. Villano JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol 2003; 14 (4): 656-8. (Pubitemid 41295100)
88. Meany HJ, Fox E, McCully C, et al. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Cancer Chemother Pharmacol 2008; 62 (3): 387-92. (Pubitemid 351871796)
89. Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007; 13 (5): 1511-5. (Pubitemid 46450442)
90. Togashi Y, Masago K, Fukudo M, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 2010; 5 (7): 950-5.
91. Porta R, Sanchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011 Mar; 37 (3): 624-31.
92. Dhruva N, Socinski MA. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 2009; 27 (22): 31-2.
93. Rogers LR, Lorusso P, Nadler P, et al. Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report. J Neurooncol 2011 Jan; 101 (2): 307-10.
94. Polli JW, Olson KL, Chism JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-3-chloro-4-(3-fluorobenzyl)oxyphenyl-6-[5-([2-(methylsulfonyl)ethy l]aminomethyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 2009; 37 (2): 439-42.
95. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008; 100: 1092-103.
96. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15 (4): 1452-9.
97. Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40 (1): 1-47.
98. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9 (2): 625-32. (Pubitemid 36182594)
99. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15 (2): 74-80. (Pubitemid 24049800)
100. Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000; 1482 (1-2): 157-71.
101. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001; 33 (2): 161-235. (Pubitemid 32703255)
102. Li J, Zhao M, He P, et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13 (12): 3731-7. (Pubitemid 46955138)
103. Ward WH, Cook PN, Slater AM, et al. Epidermal growth factor receptor tyrosine kinase: investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994; 48 (4): 659-66.
104. McKillop D, Guy SP, Spence MP, et al. Minimal contribution of desmethylgefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. Xenobiotica 2006; 36 (1): 29-39.
105. Clark GM, Zborowski DM, Santabarbara P, et al.; National Cancer Institute of Canada Clinical Trials Group. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006; 7 (6): 389-94. (Pubitemid 44043548)
106. Gridelli C, Maione P, Castaldo V, et al. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 2003; 89 (10): 1827-9. (Pubitemid 37533253)
107. Cappuzzo F, Bartolini S, Ceresoli GL, et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 2004; 90 (1): 82-6. (Pubitemid 38174943)
108. Ebi N, Semba H, Tokunaga SJ, et al. Aphase II trial of gefitinib monotherapy in chemotherapy-naive patients of75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008; 3 (10): 1166-71.
109. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20 (21): 4292-302. (Pubitemid 35266289)
110. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 (21): 2129-39. (Pubitemid 38637993)
111. Christiansen SR, Broniscer A, Panetta JC, et al. Pharmacokinetics of erlotinib for the treatmentofhigh-grade gliomainapediatric patient withcystic fibrosis: case report and review of the literature. Pharmacotherapy 2009; 29 (7): 858-66.
112. Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced nonsmall-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. J Clin Oncol 2008; 26 (14): 2350-7.
113. Gorlick R, Anders Kolb E, Houghton PJ, et al. Initial testing (stage 1) of lapatinib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2009; 53 (4): 594-8.
114. Ho C, Davis J, Anderson F, et al. Side effects related to cancer treatment: case 1. Hepatitis following treatment with gefitinib. J Clin Oncol 2005; 23 (33): 8531-3.
115. Carlini P,Papaldo P, Fabi A, etal. Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? J Clin Oncol 2006; 24 (35): 60-1.
116. Li X, Kamenecka TM, Cameron MD. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol 2009; 22 (10): 1736-42.
117. Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65 (6): 1485-95. (Pubitemid 38668306)
118. Nakamura Y, Oka M, Soda H, et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005; 65 (4): 1541-6. (Pubitemid 40270183)
119. Li J, Cusatis G, Brahmer J, et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007; 6 (3): 432-8. (Pubitemid 47328313)
120. Prados MD, Yung WK, Wen PY, et al. Phase-1 trial of gefitinib and temozolomide inpatients with malignant glioma: a North American Brain Tumor Consortium study. Cancer Chemother Pharmacol 2008; 61 (6): 1059-67. (Pubitemid 351423127)
121. Flaherty KT, Redlinger M, Schuchter LM, et al. Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with meta-static melanoma [abstract no. 3037]. Proc Am Soc Clin Oncol 2005; 23: 201s.
122. Motzer RJ, Hudes GR, Ginsberg MS, et al. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Am J Clin Oncol 2010; 33 (6): 614-8.
123. Cantarini MV, Macpherson MP, Marshall AL, et al. A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (Iressa) in healthy male volunteers. Cancer Chemother Pharmacol 2005; 56 (6): 557-62. (Pubitemid 41425051)
124. Milton DT, Riely GJ, Azzoli CG, et al. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007; 110 (3): 599-605. (Pubitemid 47106149)
125. Miller VA, Johnson DH, Krug LM, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and
126. O'Byrne KJ, Danson S, Dunlop D, et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol 2007; 25 (22): 3266-73. (Pubitemid 47325611)
127. Giaccone G, Gonzalez-Larriba JL, van Oosterom AT, et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol 2004; 15 (5): 831-8. (Pubitemid 38714747)
128. Fakih MG, Trump DL, Muindi JR, et al. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res 2007; 13 (4): 1216-23. (Pubitemid 46424063)
129. Meyerhardt JA, Clark JW, Supko JG, et al. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colo-rectal cancer. Cancer Chemother Pharmacol 2007; 60 (5): 661-70. (Pubitemid 47247278)
130. Fujita K, Ando Y, Narabayashi M, et al. Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonylox- ycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan. Drug Metab Dispos 2005; 33 (12): 1785-90. (Pubitemid 41697262)
131. Wilding G, Soulie P, Trump D, et al. Results from a pilot phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer 2006; 106 (9): 1917-24. (Pubitemid 43673206)
132. Sumitomo M, Asano T, Asakuma J, et al. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 2004; 10 (2): 794-801. (Pubitemid 38174018)
133. Hwang SW, Han HS, Lim KY, et al. Drug interaction between complementary herbal medicines and gefitinib. J Thorac Oncol 2008; 3 (8): 942-3.
134. Kuang YH, Shen T, Chen X, et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2010; 79 (2): 154-61.
135. Abbas R, Fettner S, Riek M, et al. A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyro-sine kinase inhibitor, erlotinib, in healthy subjects [abstract]. Proc Am Soc Clin Oncol 2003; 22: 548.
136. Rakhit A, Pantze MP, Fettner S, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 2008; 64 (1): 31-41.
137. Patnaik A, Wood D, Tolcher AW, et al. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res 2006; 12 (24): 7406-13. (Pubitemid 46095415)
138. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25 (12): 1545-52. (Pubitemid 46733081)
139. Duran I, Hotte SJ, Hirte H, et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007; 13 (16): 4849-57. (Pubitemid 47294792)
140. Chiorean EG, Porter JM, Foster AE, et al. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin Cancer Res 2008; 14 (4): 1131-7. (Pubitemid 351302561)
141. Ranson M, Reck M, Anthoney A, et al. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. Ann Oncol 2010; 21 (11): 2233-9.
142. Takakusa H, Wahlin MD, Zhao C, et al. Metabolic-intermediate complex formation of human cytochrome P450 3A4 by lapatinib. Drug Metab Dispos. Epub 2011 Mar 1.
143. Dunne G, Breen L, Collins DM, et al. Modulation of P-gp expression by lapatinib. Invest New Drugs. Epub 2010 Jul 6.
144. Collins DM, Crown J, O'Donovan N, et al. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Invest New Drugs 2010; 28 (4): 433-44.
145. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat nonAIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol 2009; 21: 445-54.
146. Midgley RS, Kerr DJ, Flaherty KT, et al. A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol 2007; 18: 2025-9. (Pubitemid 350286244)
147. Siegel-Lakhai WS, Beijnen JH, Vervenne WL, et al. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res 2007; 13 (15): 4495-502. (Pubitemid 47219719)
148. Storniolo AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008; 26 (20): 3317-23.
149. Lo Russo PM, Jones SF, Koch KM, et al. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 2008; 26: 3051-6.
150. Chu QSC, Cianfrocca ME, Goldstein LJ, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res 2008; 14 (14): 4484-90.
151. Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 2011; 10 (3): 531-9.
152. Cusatis G, Sparreboom A. Pharmacogenomic importance of ABCG2. Pharmacogenomics 2008; 9 (8): 1005-9.
153. Shi Z, Peng XX, Kim IW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007; 67 (22): 11012-20. (Pubitemid 350145931)
154. Marchetti S, de Vries NA, Buckle T, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/(triple-knockout) and wild-type mice. Mol Cancer Ther 2008; 7 (8): 2280-7.
155. Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004; 10 (14): 4607-13 (Pubitemid 38955509)